Effect of viscous additives on the absorption and hepatic disposition of 5-fluorouracil (5-FU) after application to liver surface in rats

被引:5
作者
Kodama, Yukinobu [1 ]
Horishita, Miyuki [1 ]
Fumoto, Shintaro [1 ]
Mine, Toyoharu [1 ]
Miyamoto, Hirotaka [1 ]
Yoshikawa, Naoki [1 ]
Hirata, Haruna [1 ]
Sasaki, Hitoshi [2 ]
Nakamura, Junzo [1 ]
Nishida, Koyo [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan
[2] Nagasaki Univ Hosp, Dept Hosp Pharm, Nagasaki, Japan
关键词
5-fluorouracil; absorption; controlled release; liver surface; viscous additive; BIOADHESIVE CERVICAL PATCH; PHENOL RED; IN-VITRO; HEPATOCELLULAR-CARCINOMA; OCULAR EVALUATION; DRUG ABSORPTION; INJECTABLE GEL; MODEL-DRUGS; DELIVERY; MEMBRANE;
D O I
10.1111/j.2042-7158.2012.01514.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives The aim was to study the effect of viscous additives on the absorption and hepatic disposition of 5-fluorouracil (5-FU) after application to the liver surface in rats. Methods 5-FU solution with or without viscous additives was applied to the rat liver surface with a cylindrical diffusion cell. Then, blood and the remaining solution in the diffusion cell were collected at selected times, followed by excision of the liver. The excised liver was divided into three sites and assayed for 5-FU content. Key findings The absorption rate of 5-FU from the liver surface was decreased in the presence of carboxymethylcellulose sodium (CMC-Na) and polyvinyl alcohol (PVA) as compared with the control. The ka values of PVA 15% and CMC-Na 1% were reduced to about 80 and 67% of the control. The maximum plasma concentration of 5-FU was decreased by incorporation of viscous additives. The 5-FU concentration at the diffusion cell attachment site of the liver (site 1) plateaued at 180 min in the absence of viscous additives. On the other hand, the concentration of 5-FU at site 1 increased in a time-dependent manner until 360 min in the presence of viscous additives. Conclusion Viscous additives might be useful for retaining drugs at their application site and controlling the rate of absorption from the liver surface.
引用
收藏
页码:1438 / 1444
页数:7
相关论文
共 39 条
  • [31] Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts
    Smith, JP
    Kanekal, S
    Patawaran, MB
    Chen, JY
    Jones, RE
    Orenberg, EK
    Yu, NY
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (04) : 267 - 274
  • [32] Buccal absorption of ergotamine tartrate using the bioadhesive tablet system in guinea-pigs
    Tsutsumi, K
    Obata, Y
    Nagai, T
    Loftsson, T
    Takayama, K
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 238 (1-2) : 161 - 170
  • [33] CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours
    Vogl, TJ
    Engelmann, K
    Mack, MG
    Straub, R
    Zangos, S
    Eichler, K
    Hochmuth, K
    Orenberg, E
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (04) : 524 - 529
  • [34] WATANABE J, 1985, CHEM PHARM BULL, V33, P1187
  • [35] LIQUID SCINTILLATION SPECTROMETRY OF 5-FLUOROURACIL IN CERVICAL TISSUE FOLLOWING IN-VITRO SURFACE APPLICATION OF A BIOADHESIVE CERVICAL PATCH
    WOOLFSON, AD
    MCCAFFERTY, DF
    MCCARRON, PA
    PRICE, JH
    [J]. PHARMACEUTICAL RESEARCH, 1994, 11 (09) : 1315 - 1319
  • [36] AUTORADIOGRAPHIC IMAGING OF THE DISTRIBUTION OF 5-FLUOROURACIL THROUGH CERVICAL TISSUE FOLLOWING IN-VITRO SURFACE APPLICATION OF A BIOADHESIVE CERVICAL PATCH
    WOOLFSON, AD
    MCCAFFERTY, DF
    MCCARRON, PA
    PRICE, JH
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (05) : 676 - 681
  • [37] STATISTICAL MOMENTS IN PHARMACOKINETICS
    YAMAOKA, K
    NAKAGAWA, T
    UNO, T
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06): : 547 - 558
  • [38] COMPARISON OF BODY DISTRIBUTION OF POLY(VINYL ALCOHOL) WITH OTHER WATER-SOLUBLE POLYMERS AFTER INTRAVENOUS ADMINISTRATION
    YAMAOKA, T
    TABATA, Y
    IKADA, Y
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (06) : 479 - 486
  • [39] YU NY, 1995, CANCER CHEMOTH PHARM, V36, P27